Skip to main content

Clinical Trials Using Anti-HER3/Topoisomerase I Inhibitor Antibody-drug Conjugate

Review the clinical trials studying anti-her3/topoisomerase I inhibitor antibody-drug conjugate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Status: Active
Location: 8 locations
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 5 locations
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Status: Active
Location: 7 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Status: Active
Location: 4 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Status: Active
Location: 4 locations
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Status: Active
Location: 3 locations
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Status: Active
Location: 3 locations
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Status: Active
Location: 2 locations
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Active
Location: 2 locations
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Patritumab Deruxtecan for the Treatment of Patients with Newly Diagnosed or Recurrent Brain Metastases
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Status: Active
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Status: Active
Location: 6 locations
A Study of DM002 in Patients With Advanced Solid Tumors
Status: Active
Location: 2 locations
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Status: Active
Location: See ClinicalTrials.gov
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia